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Abstract
Individuals with HIV experience fluctuating levels of distress throughout the course of HIV infection. This study
was conducted to examine the associations of depressive symptomatology with HIV disease in a cohort of
individuals who are engaged in routine medical care. This cross-sectional study examined the prevalence of
depressive symptoms that were measured as part of a standard of care behavioral assessment among individuals
at an urban HIV clinic in the Midwest. Demographic characteristics, depressive symptoms, and behavioral risk
factors were collected. A total of 514 individuals participated in the study, the majority of whom was male and
African American. One quarter of the sample endorsed symptoms of other depressive disorder, while 18% (n¼ 91)
endorsed symptoms of major depressive disorder as measured by the Patient Health Questionnaire-9 (PHQ-9).
Among those on highly active antiretroviral therapy (HAART), individuals whowere unemployed (adjusted odds
ratio [AOR]¼ 2.47, 95% confidence interval [CI]¼ 1.54, 3.97), had a minor dependent (AOR¼ 2.17, 95% CI¼ 1.25,
3.77), or between the ages of 18 and 34 years (AOR¼ 1.37, CI¼ 1.03, 1.94) and detectable HIV viral load
(AOR¼ 2.52, 95% CI¼ 1.22, 5.23) were more likely to report depressive disorder symptoms when controlling for
age, gender, race, and education. Nearly 15% of the sample endorsed having suicidal thoughts at least once in the
past twoweeks. Regardless of HAART prescription, individuals whowere unemployed had a higher likelihood of
expressing suicidal ideation (AOR¼ 3.43, 95% CI¼ 1.66, 7.06). Given the association between depressive symp-
tomatology and poor rates of HIV viral suppression, screening and appropriate interventions for depressive
symptoms are warranted in the HIV outpatient setting to improve outcomes.
Introduction
Significant advances have beenmade toward improvingthe efficacy and availability of medical treatments for HIV
disease.1 As individuals are living longer with HIV infection,
quality of life issues and secondary prevention efforts have
been increasingly incorporated into comprehensive care
practices.2 It is well documented that individuals with HIV
have significantly higher levels of psychological distress than
the general population and are impacted by fluctuating levels
of distress throughout the course of HIV infection.3–6 During
periods of distress, individuals with a chronic illness not only
have lower quality of life, but also have more difficulty en-
gaging in behaviors that are health promoting.7–9 There has
been little documented that examined the effect highly active
antiretroviral therapy (HAART) on depression among indi-
viduals with HIV. Having a better understanding of the re-
lationship between HAART and depression will enhance
provision of care.
Depression has been documented as the most common
form of psychological distress experienced by individuals
with HIV=AIDS.4–7,8,10 The impact of depression on immune
function is not well defined, yet significant negative associa-
tionshavebeenreportedregarding increasedrisk forsubstance
use disorders, inconsistent use of condoms, nonadherence to
HAART and routine medical care.9–16 African Americans and
women have been identified as groups who often have unrec-
ognized or untreated depressive symptoms that may impact
HIV-related health outcomes.17–22 Individual interventions
have been developed to address these negative mood disor-
ders among HIV-infected populations and have been shown
to be successful.23
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As a result of the established relationship between HIV
disease and depressive disorders, screening for depressive
symptoms has been recommended as a component of routine
HIV medical care.2,24 Unfortunately, consistent screening
among patients who present for care has been difficult to es-
tablish in many care-providing environments. This study was
conducted to assess the prevalence of symptoms of depressive
disorders and understand their associations to HIV-related
health outcomes among an urban cohort of individuals with
HIV receiving medical care.
Methods
This cross-sectional study examined rates of depressive
symptoms measured in a behavioral assessment, which was
conducted as part of standard of care among HIV-infected
patients in an urban, Midwestern university HIV clinic. All
patients with HIV who presented at the clinic between June
and September 2007 were eligible to complete assessments
that were conducted as part of their clinic visit. This studywas
approved by Washington University School of Medicine
Human Research Protection Office.
Demographic characteristics (race, age, employment, edu-
cation, income,andgender),depressivesymptoms,andbehav-
ioral risk factors (current sexual and drug-using behaviors)
were collected. The Patient Health Questionnaire (PHQ-9)
was used to measure depressive symptomatology, severity of
depressive symptoms, and calculate symptom counts that
signify major depressive disorder and other depressive dis-
orders. Each of the PHQ-9 items are rated using a Likert-type
scale from 0–3, with a range of 0–27.25
The PHQ-9 focuses on the nine diagnostic criteria for
Diagnostic and Statistical Manual of Mental Disorders, 4th edition
(DSM-IV) depressive disorders and is very brief. The PHQ-9
can be self-administered or interviewer-administered and is
well-validated in the United States as a dual-purpose instru-
ment that yields both a measure of depression severity and
criteria-based diagnoses ofDSM-IV depressive disorders: ma-
jor depressive disorder (MDD), other depressive disorder
(ODD), and any depressive disorder (i.e., MDD or ODD).25,26
It has also been successfully used in diverse populations,
specifically those with HIV.26,27 Rather than using the differ-
ences in diagnoses of ODD and MDD, we dichotomized the
depressive disorder diagnoses (depressive disorder versus
minimal or no depressive symptoms), since the nine items
from the instrument provide a method to calculate a count of
symptoms and severity to identify these disorders.
Medical measures including current CD4 cell count, plas-
ma HIV RNA level, and use of antiretroviral therapies were
collected from time of the visit. HIV viral load measures are
used as proxy for medication adherence. Highly active anti-
retroviral therapy (HAART) was defined as the use of three or
more antiretroviral drugs that included a protease inhibitor or
a non-nucleoside reverse transcriptase inhibitor. Virologic
suppression was defined as having an HIV RNA of less than
400 copies per milliliter.
Statistical analyses
Descriptive and bivariate analyses were conducted to il-
lustrate and assess differences between gender, race, therapy
types, andHIV viral load among the sample. w2 analyses were
conducted for dichotomous variables and independent sam-
ple t tests for continuous variables with depressive disorder
symptoms and suicidal ideation as the outcome variables.
Analyses that were assessed with the outcome variable of
suicidal ideation were conducted among those who had en-
dorsed any suicidal ideation in the past 2 weeks. Education
levels were dichotomously defined (high school degree or less
and more than a high school degree). There were few non-
African American minorities (n¼ 46) and individuals who
reported their race as ‘‘other,’’ therefore racewasdichotomized
into Caucasian versus African Americans=other racial=ethnic
minorities. Employment status was dichotomized into unem-
ployed (including receiving disability benefits) and employed
(part time or full time). There were participants who refused
to respond to annual income (n¼ 44). Minimal data were
missing among the employment status (n¼ 1) and number of
minor dependents (n¼ 7) variables. Income was not used in
the analyses due to its theoretical correlation with employ-
ment status among this population, actual correlation was
calculated (r¼ 0.47). Therefore, the missing data forced a
smaller sample size, by listwise deletion in SPSS, for the lo-
gistic regression analyses (n¼ 510 regardless of HAART
prescription). Logistic regression analyses were conducted to
confirm the bivariate analyses, with having symptoms of
depressive disorders and suicidal ideation as the outcome
variables. All tests were two-tailed and p< 0.05 was consid-
ered significant. Data analyses were performed using SPSS
software (version 16.0, SPSS Inc., Chicago, IL).
Results
A total of 514 individuals completed the assessments. The
majority of the sample was male (n¼ 348; 68%) and African
American (n¼ 305; 60%). The mean age of the sample was 42
years (11). Half of the sample reported having a high school
education or less (n¼ 254) and half (n¼ 260) completed a
college or graduate degree. Nearly half of the sample reported
an annual salary of less than $10,000 (n¼ 239; 47%), while 16%
(n¼ 76) reported a 12-month salary of greater than $30,000.
One fifth of the patients reported being unemployed (n¼ 110),
32% (n¼ 164) reported receiving disability benefits, and 41%
(n¼ 209) were employed either part time (n¼ 51; 10%) or full
time (n¼ 158; 31%). One quarter (n¼ 129) of the sample re-
ported supporting one or more individuals who were under
18 years of age in their household. Table 1 shares the demo-
graphic characteristics of the sample.
Depressive symptomatology
One quarter of the sample (n¼ 129) endorsed symptoms of
ODDs, while 18% (n¼ 91) endorsed symptoms of MDD.
These two categories were combined for subsequent analyses.
Almost 15% of the sample (n¼ 74) endorsed having suicidal
thoughts at least once in the past 2 weeks.
Women, African American or other minorities, individuals
who were unemployed, and those who had minor depen-
dents had higher odds of reporting depressive disorder
symptoms inunivariateanalyses.Whencontrolling forgender,
race, education, and current HAART prescription, individu-
als with minor dependents and those who were unemployed
had higher odds of expressing depressive disorder symptoms.
Among individuals currently prescribed HAART, univariate
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analyses revealed that individuals between 18 and 34 years,
women, African American or other minorities, those with
minor dependents, those who were unemployed, and those
with detectable viral loads expressed higher rates of depres-
sive disorder symptoms. When controlling for gender, race,
and education, those who were unemployed and had minor
dependents had higher odds of having depressive disorder
symptoms. Even among those on HAART, individuals with
unsuppressed viremia had 2.52 times (95% confidence inter-
val [CI]¼ 1.22, 5.23) higher odds to express depressive dis-
order symptoms. See Table 2 for detailed relationships of
these factors. The Hosmer and Lemeshow goodness-of-fit
statistic for the model was acceptable with p> 0.05 at each
decile.
There were no differences in suicidal ideation by gender,
race, age, supporting a minor dependent, education, and
currently being onHAART (Table 3). Among the total sample,
individuals who were unemployed had higher odds of ex-
pressing suicidal ideation (odds ratio [OR]: 2.62, 95%
CI¼ 1.48, 4.65). Higher rates of suicidal ideation were related
to higher rates of depressive disorder symptoms. In adjusted
analyses, individuals who were unemployed had 2.65 (95%
CI¼ 1.49, 4.70) times higher odds to express suicidal ideation.
Among those on HAART, employment status was the only
demographic association related to suicidal ideation in both
unadjusted and adjusted analyses. The Hosmer and Leme-
show goodness-of-fit statistic was acceptable in both of the
models with p> 0.05 at each decile.
Discussion
The findings of our study highlight the need to actively
screen and treat individuals with HIV for symptoms of de-
pression. We found considerable prevalence of symptoms of
depressive disorders and suicidal ideation among individuals
seeking medical care in this urban outpatient HIV clinic.28 By
bivariate analyses, there were significant associations be-
tween gender, employment, and having minor dependents
with symptoms of depressive disorders. Having active vire-
mia was also associated with symptoms of depressive disor-
ders. Increased risk of depressive disorder symptoms were
unemployment, supporting minor dependents, and having
detectable viral load.
Suicidal ideation in the current HAART era is poorly de-
scribed. Several reports regarding suicidal ideation have re-
lated these symptoms to limited treatment opportunities.4,29,30
Suicidal ideation was associated with employment status and
annual income. Specifically, those who were unemployed as
well as those who reported having an annual income of
$10,000 or less were more likely to have had symptoms of
suicidal ideation within the past 2 weeks. Our study found no
relationship between detectable HIV viral load and suicidal
ideation, which is contrary to previous research suggesting
that suicidal ideation is more likely to occur with advanced
HIV and disease progression.29–31 However, more research is
warranted to understand suicidal ideation in the current
HAART era.
Depression has been the most commonly reported symp-
tom of distress among individuals with HIV.5,16,32 It is well
documented that individuals with HIV have higher rates of
depression than individuals without HIV.3,8,31 The relation-
ship revealed in this study that depression may have an im-
pact on virologic suppression is considerable. These findings
demand further attention with longitudinal examination with
regular depressive symptomatology screening to learn de-
pressive patterns change over time and correlates of those
changes. While these results are not unique, the importance of
screening depressive symptoms is paramount in the com-
prehensive care of individuals with HIV.9,14,33,34 Screening
and treatment of depression could potentially improve
health-protective behaviors. Increasing understanding of the
individual challenges of living with HIV may allow further
interventions to reduce HIV transmission and improve HIV-
related health outcomes. Furthermore, this routine screening
of depression may offer an important opportunity to allow
individuals who have never before examined their psycho-
logical distress symptoms and levels.18 HIV-related support
services have created a chance for individuals to seek mental
health care as an important component of a comprehensive
care model.35
Unemployment has previously been associatedwith higher
rates of depressive symptoms, lower quality of life, and higher
levels of HIV RNA and lower CD4 cell counts, as was found in
this study.36,37 In the era prior to HAART, individuals were
leavingwork due to advancedAIDS, opportunistic infections,
medication side effects, and shorter life expectancy. With the
improvements in treatment, individuals have the opportunity
to continue or return to work, which has been associated with
Table 1. Clinic Sample Demographic and HIV-Related







African American 305 59.3
Other 46 8.9
Age Category
18–34 years 141 27.9
35–49 years 253 50.0
50 years 112 22.1
Children in home (n¼ 507)
No minor dependents 378 74.6








High school degree 254 49.4
>High school degree 260 50.6
HAART prescription
Currently on HAART 370 72.0
Not on HAART 144 28.0
Viral load (on HAART)
<400 copies=mL 330 89.2
400 copies=mL 40 10.8
HAART, highly active antiretroviral therapy.
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better quality of life, less psychological distress, and increased
socioeconomic status.37–40 Yet, returning to work continues to
be a challenge for individuals with HIV; these challenges in-
clude health insurance coverage, serostatus disclosure to co-
workers and experienced stigma at work.36 Therefore, the
continued nature of overall psychological distress and stress-
ors may perpetuate challenges with treatment and disease
progression.
The causal relationship between HIV viral loads and de-
pressive symptomatology is impossible to disentangle with-
out a longitudinal examination. In this study, regression
models suggested that virologic suppression and therefore
medication adherence, for which it is a good proxy, was lower
among those with more depressive symptoms. Furthermore,
we conducted analyses controlling for all individuals who
were receiving HAART and found the same results: having a
detectable viral load, being unemployed, and having minor
dependents places individuals at increased odds for depres-
sive disorder symptoms. It is unclear if individuals are ex-
periencing high levels of distress and therefore, not taking
their HIV medications with resultant suboptimal viral load
suppression or whether ongoing uncontrolled viremia causes
depression.Whilewe cannot elucidate a definitive pathway, it
is clear that higher levels of depressive symptomatology are
negatively related to virologic suppression.
Caring for children or other minor dependents may serve
as an additional stressor in the lives of individuals with HIV
that leads to higher rates of depression. Similar findings have
been reported, yet few examinations have assessed causal
relationships.41,42 Serostatus disclosure to children at home,
medication adherence, and having symptoms of HIV disease
may function synergistically in developing this depressive
symptomatology, yet derivation of the stressor is unclear and
could be clarified with longitudinal examination. A better
understanding of the longitudinal impact of having minor
dependents on the distress levels will provide intervention
opportunities for the caregiverswithHIV.Additionally, impli-
cations to the care for parents with HIV are significant. These
findings highlight the elevated levels of psychological distress
that have been found among women and mothers with
HIV.41,43 Exploring relationships of distress among women
with children is important to understand how to best inter-
vene in the clinic environment to support their daily lives.
The related limitations are evident for this cross-sectional
study design of one outpatient clinic population. This study
uses a depression screening tool that has been shown to be
Table 2. Depressive Disorder Symptoms by Characteristic of the Total Study Sample and those on HAART























18–34 years 63 44.7 45 54.9 1.93 (1.15, 3.23)a 1.37 (1.03, 1.94)
35–49 years 119 46.5 80 41.9 Ref Ref
50 years 44 38.9 31 33.0 Ref Ref
Gender
Male 141 40.9 Ref 101 38.8 Ref
Female 85 51.5 1.54 (1.06, 2.23)a 55 51.4 1.67 (1.06, 2.62)a
Race
Caucasian 59 36.9 Ref 45 34.4 Ref
African American=
Other minorities
167 47.7 1.56 (1.06, 2.29)a 111 47.0 1.70 (1.09, 2.64)a
Children in home
No minor dependents 151 40.3 Ref Ref 104 37.5 Ref Ref
1 Minor dependent 71 55.5 1.85 (1.23, 2.78)a 2.10 (1.37, 3.21)b 49 58.3 2.33 (1.42, 3.83)b 2.17 (1.25, 3.77)a
Employment status
Employed 63 30.4 Ref Ref 47 32.2 Ref Ref
Unemployed 162 53.6 2.65 (1.82, 3.82)b 2.98 (2.26, 4.38)b 108 49.1 2.03 (1.31, 3.14)b 2.47 (1.54, 3.97)b
Education
High school degree 121 48.0 Ref 74 44.6 1.17 (1.30, 1.77)
High school degree 105 40.7 1.35 (1.06, 1.91) 82 40.8 Ref
HAART Prescription
Currently on HAART 156 42.5 Ref N=A N=A N=A
Not on HAART 70 49.0 1.30 (1.36, 1.91)
Viral load
<400 copies=mL N=A N=A N=A N=A 130 39.8 Ref Ref
400 copies=mL 26 65.0 2.81 (1.42, 5.59)a 2.52 (1.22, 5.23)a
ap< 0.05.
bp< 0.001.
HAART, highly active antiretroviral therapy; ODD, other depressive disorder; MDD, major depressive disorder.
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appropriate, yet as with all screening may be overly sensitive
to symptoms that may not indicate diagnoses.25 These results
do not offer insight to the causal relationship of these factors,
although they are able to highlight the need for longitudinal
examination to offer opportunity for improved intervention.
This study served to examine the prevalence and severity of
depressive symptomatology in an HIV outpatient clinic in the
United States. These findings stress the importance of screen-
ing and treatment of depression as an integral component of
HIV care. Future research should examine causal relation-
ships of sociodemographic factors that may serve as indica-
tors of higher depressive symptomatology.
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